Business
Rakovina Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference
VANCOUVER, British Columbia, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. ( ...
About this update from Rakovina Therapeutics Inc
[{"type":"text","content":"Rakovina Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference\n\n\n\n VANCOUVER, British Columbia, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (“Rakovina” or the “Company”) (TSX-V: RKV) (FSE: 7JO0), a biopharmaceutical company advancing cancer therapies through AI-powered drug discovery, today announced that Executive Chairman, Jeffrey Bacha, and Chief Financial Officer, Dr. David Kideckel, will attend and present at the H.C. Wainwright 27th Annual Global Investment Conference, taking place September 8\n \n th\n \n -10\n \n th\n \n in New York City.\n \n\n Mr. Bacha will present an overview of Rakovina’s research and development pipeline, corporate strategy, and upcoming milestones. The presentation will be accessible to registered conference attendees, with a recording made available on Rakovina’s website and social media channels following the event. Throughout the conference, management will also participate in one-to-one meetings with institutional investors.\n \n\n\n Recent Corporate Highlights\n \n\n\n Rakovina has achieved numerous important milestones through the first half and into the second half of 2025 that underscore the Company’s progress and momentum:\n \n\n\n\n\n Presented new preclinical data at the American Association for Cancer Research (AACR) Annual Meeting\n \n\n ;\n \n\n\n\n Obtained DTC eligibility – streamlining the investment process for U.S. investors, enhancing liquidity and broadening market accessibility\n \n\n ;\n \n\n\n\n Advanced the KT-5000AI program, yielding potent ATR inhibitor candidates from AI-enabled screening\n \n\n ;\n \n\n\n\n Announced a non-binding Letter of Intent with Saudi-based NanoPalm Ltd. to form a joint venture pairing AI-discovered oncology therapeutics with patterned lipid nanoparticle (pLNP) delivery systems.\n \n\n\n\n\n “We welcome the opportunity to meet with global investors at H.C. Wainwright to discuss how Rakovina is building value through our AI-enabled pipeline,” said Jeffrey Bacha, Executive Chairman of Rakovina Therapeutics. “With the achievement of recent milestones in our programs and the advancement toward a JV partnership, we are well positioned for the next phase of development.”\n \n\n\n\n About the H.C. Wainwright 27th A...